Tocilizumab use in giant cell arteritis: comparing Pharmaceutical Benefits Scheme eligible and ineligible cases in South Australia
Internal Medicine Journal · 2024
DOI: 10.1111/imj.16419 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Internal Medicine Journal, 2024. Verfasst von Lucinda Robinson und 6 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatology Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia. Hauptthemen laut MEDLINE: Giant Cell Arteritis, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 9 Literaturangaben.
Abstract (Originalsprache)
Tocilizumab (TCZ) is increasingly used as a steroid‐sparing agent in giant cell arteritis (GCA), but there are strict Pharmaceutical Benefits Scheme (PBS) restrictions for its use in Australia. Patients who do not meet the PBS criteria can obtain TCZ through public hospital individual patient use (IPU) schemes which may not be universally accessible. We compared patients receiving IPU‐approved TCZ with patients receiving PBS‐subsidised TCZ and found IPU approvals were granted mainly for visual loss, a serious complication of GCA, in patients who otherwise failed to meet PBS criteria. Further studies demonstrating that TCZ is comparatively more effective than prednisolone monotherapy, as well as cost‐effective, are needed to substantiate the rationale for expanding PBS approval criteria.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Rheumatology Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
- Pharmacy Department, Central Adelaide Local Health Network, Adelaide, South Australia, Australia.
- University of Adelaide, Adelaide, South Australia, Australia.
- Ophthalmology Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
- Rheumatology Unit, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia.
ORCID-Profile: Lucinda Robinson, Catherine Hill
Zitieren
APA
Robinson, L., Hamden, M., Griggs, K., Simon, S., Hill, C., Limaye, V., & Proudman, S. (2024). Tocilizumab use in giant cell arteritis: comparing Pharmaceutical Benefits Scheme eligible and ineligible cases in South Australia. Internal Medicine Journal. https://doi.org/10.1111/imj.16419
Vancouver
Robinson L, Hamden M, Griggs K, Simon S, Hill C, Limaye V, et al. Tocilizumab use in giant cell arteritis: comparing Pharmaceutical Benefits Scheme eligible and ineligible cases in South Australia. Internal Medicine Journal. 2024. doi:10.1111/imj.16419
BibTeX
@article{Robinson2024,
author = {Robinson, Lucinda and Hamden, Maddison and Griggs, Kim and Simon, Sumu and Hill, Catherine and Limaye, Vidya and Proudman, Susanna},
title = {Tocilizumab use in giant cell arteritis: comparing Pharmaceutical Benefits Scheme eligible and ineligible cases in South Australia},
journal = {Internal Medicine Journal},
year = {2024},
doi = {10.1111/imj.16419}
}
EUVIMED